Latus Bio closed a $97 million Series A to advance an AAV-capsid variant platform for gene therapies, with initial clinical data expected from two lead programs: LTS-201 for Huntington’s disease and LTS-101 for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2). The financing supports operations through milestone-based development, including first clinical signals from the most advanced assets. The company is positioned as a next-generation gene therapy player focused on enabling delivery at lower doses, aiming to address manufacturing and tolerability constraints seen in the category. Its pipeline includes a Huntington’s program designed for broad target engagement in the central nervous system and a CLN2 asset targeting lysosomal disease. This funding also arrives after separate coverage that Latus has started its first clinical trials for an initial wave of programs, highlighting execution pace rather than platform-only ambitions. For biotech investors and development teams, the near-term question will be whether Latus can demonstrate consistent translatability from vector performance to clinical pharmacodynamics and safety in the first patient cohorts.